Cantor Fitzgerald L. P. Makes New $653,000 Investment in Denali Therapeutics Inc. $DNLI

Cantor Fitzgerald L. P. acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 45,000 shares of the company’s stock, valued at approximately $653,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. AlphaQuest LLC increased its position in Denali Therapeutics by 224.1% in the third quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock worth $1,081,000 after purchasing an additional 51,458 shares during the last quarter. Aberdeen Group plc lifted its position in Denali Therapeutics by 23.4% during the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after purchasing an additional 210,835 shares during the last quarter. Principal Financial Group Inc. lifted its position in Denali Therapeutics by 18.5% during the third quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after purchasing an additional 198,207 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Denali Therapeutics by 32.5% in the 2nd quarter. Schroder Investment Management Group now owns 386,539 shares of the company’s stock worth $5,408,000 after buying an additional 94,744 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Denali Therapeutics in the 2nd quarter worth $55,224,000. 92.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

DNLI has been the topic of several recent research reports. Morgan Stanley restated an “overweight” rating and set a $40.00 target price on shares of Denali Therapeutics in a research report on Thursday, January 8th. Wedbush dropped their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Stifel Nicolaus set a $37.00 price objective on Denali Therapeutics in a research note on Monday, November 17th. Wolfe Research started coverage on Denali Therapeutics in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Finally, UBS Group assumed coverage on Denali Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Insiders Place Their Bets

In related news, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This trade represents a 5.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.50% of the stock is owned by insiders.

Denali Therapeutics Stock Performance

Denali Therapeutics stock opened at $20.57 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The firm has a market capitalization of $3.26 billion, a P/E ratio of -6.93 and a beta of 1.02. Denali Therapeutics Inc. has a 1-year low of $10.57 and a 1-year high of $23.77. The company’s 50-day moving average is $19.87 and its 200 day moving average is $17.51.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the prior year, the firm posted ($0.67) EPS. Research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.